Biomarker Discovery and Exploration for SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer.
Testing is usually incorporated at diagnosis or during disease progression to guide therapeutic decisions.
Unmet needs include a lack of validated biomarkers and standardized testing protocols in SCLC.
Future solutions involve research to identify reliable biomarkers and development of standardized testing guidelines.

Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring the existing unmet needs in biomarker testing for SCLC and potential strategies to address and overcome these challenges in the future.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

Now Viewing

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

What is the role of biomarker testing in your patients with small cell lung cancer (SCLC)? When in their treatment journey do you incorporate it?

What are the current unmet needs with biomarker testing in SCLC, and how can they be addressed and overcome in the future?